| Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin | Frank Vinluan | 10/14/20 | Boston |
| Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma | Frank Vinluan | 10/13/20 | San Diego |
| SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D | Frank Vinluan | 10/12/20 | Boston |
| “Opioid Stacking” Concerns Lead FDA to Reject Avenue Therapeutics Drug | Frank Vinluan | 10/12/20 | New York |
| Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More | Frank Vinluan | 10/09/20 | National |
| BIO Launches ‘Biotech Votes’ Campaign to Encourage Registration and Informed Voting | Editors | 10/08/20 | Boston |
| Bristol Myers to Buy MyoKardia, FDA-Ready Heart Disease Drug for $13.1B | Frank Vinluan | 10/05/20 | New York |
| Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More | Frank Vinluan | 10/02/20 | National |
| FDA Lifts Solid Bio Clinical Hold, Duchenne Study Cleared to Resume | Frank Vinluan | 10/01/20 | Boston |
| Pfizer Pumps $200M Into CStone for Rights to PD-L1 Cancer Drug in China | Frank Vinluan | 09/30/20 | New York |
| With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug | Frank Vinluan | 09/30/20 | New York |
| Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs | Frank Vinluan | 09/28/20 | Boston |
| Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More | Frank Vinluan | 09/25/20 | National |
| Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs | Frank Vinluan | 09/24/20 | Boston |
| Xconomy Awards On-Demand ‘Meet the Finalists’ Webcast Series Continues This Week | Editors | 09/21/20 | Boston |
| Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More | Frank Vinluan | 09/18/20 | National |
| Moderna CMO Talks COVID-19 Vaccine at the Xcelerate Keynote Series | Editors | 09/16/20 | Boston |
| Neogene Therapeutics Grabs $110M to Tackle Solid Tumors With Cell Therapy | Frank Vinluan | 09/15/20 | Europe |
| Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals | Frank Vinluan | 09/14/20 | Seattle |
| Gilead Adds “Cornerstone” Cancer Drug in $21B Immunomedics Buyout | Frank Vinluan | 09/14/20 | San Francisco |
| Join Xconomy Next Week at the Virtual Xcelerate Keynote Series at Biotech Week Boston | Editors | 09/14/20 | Boston |
| Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More | Frank Vinluan | 09/11/20 | National |
| Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More | Frank Vinluan | 09/04/20 | National |
| Reeling From FDA Rejection, Intercept Pharma Slashes Headcount by 25% | Frank Vinluan | 09/01/20 | New York |
| Early Bird Sale for Xcelerate at Biotech Week Boston Ends This Friday | Editors | 08/31/20 | Boston |
| Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More | Frank Vinluan | 08/28/20 | National |
| Athira Aims for the Nasdaq to Advance Alzheimer’s Drug to Phase 2 Tests | Frank Vinluan | 08/27/20 | Seattle |
| AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial | Sarah de Crescenzo | 08/27/20 | New York |
| Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases | Frank Vinluan | 08/26/20 | Boston |
| FDA Adds Plasma as 2nd COVID-19 Treatment Under Emergency Guidelines | Sarah de Crescenzo | 08/24/20 | National |
